Literature DB >> 25814526

Hyperglycemia repression of miR-24 coordinately upregulates endothelial cell expression and secretion of von Willebrand factor.

Yaozu Xiang1, Jijun Cheng2, Dandan Wang1, Xiaoyue Hu1, Yi Xie1, Jeremiah Stitham1, Gourg Atteya1, Jing Du1, Wai Ho Tang1, Seung Hee Lee1, Kristen Leslie1, Geralyn Spollett3, Zejian Liu3, Erica Herzog4, Raimund I Herzog3, Jun Lu2, Kathleen A Martin1, John Hwa1.   

Abstract

An elevated level of von Willebrand factor (VWF) in diabetic patients is associated with increased risk of thrombotic cardiovascular events. The underlying mechanism of how VWF expression is upregulated in diabetes mellitus is poorly understood. We now report that hyperglycemia-induced repression of microRNA-24 (miR-24) increases VWF expression and secretion in diabetes mellitus. In diabetic patients and diabetic mouse models (streptozotocin/high-fat diet-induced and db/db mice), miR-24 is reduced in both tissues and plasma. Knockdown of miR-24 in mice leads to increased VWF mRNA and protein levels and enhanced platelet tethering (spontaneous thrombosis). miR-24 tightly controls VWF levels through pleiotropic effects, including direct binding to the 3' untranslated region of VWF and targeting FURIN and the histamine H1 receptor, known regulators of VWF processing and secretion in endothelial cells. We present a novel mechanism for miR-24 downregulation through hyperglycemia-induced activation of aldose reductase, reactive oxygen species, and c-Myc. These findings support a critical role for hyperglycemic repression of miR-24 in VWF-induced pathology. miR-24 represents a novel therapeutic target to prevent adverse thrombotic events in patients with diabetes mellitus.
© 2015 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25814526      PMCID: PMC4447857          DOI: 10.1182/blood-2015-01-620278

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  62 in total

1.  von Willebrand factor and coronary heart disease: prospective study and meta-analysis.

Authors:  P H Whincup; J Danesh; M Walker; L Lennon; A Thomson; P Appleby; A Rumley; G D O Lowe
Journal:  Eur Heart J       Date:  2002-11       Impact factor: 29.983

2.  Inducible secretion of large, biologically potent von Willebrand factor multimers.

Authors:  L A Sporn; V J Marder; D D Wagner
Journal:  Cell       Date:  1986-07-18       Impact factor: 41.582

3.  Structure of von Willebrand factor-cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura.

Authors:  X Zheng; D Chung; T K Takayama; E M Majerus; J E Sadler; K Fujikawa
Journal:  J Biol Chem       Date:  2001-09-13       Impact factor: 5.157

4.  Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura.

Authors:  G G Levy; W C Nichols; E C Lian; T Foroud; J N McClintick; B M McGee; A Y Yang; D R Siemieniak; K R Stark; R Gruppo; R Sarode; S B Shurin; V Chandrasekaran; S P Stabler; H Sabio; E E Bouhassira; J D Upshaw; D Ginsburg; H M Tsai
Journal:  Nature       Date:  2001-10-04       Impact factor: 49.962

5.  C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease.

Authors:  John Danesh; Jeremy G Wheeler; Gideon M Hirschfield; Shinichi Eda; Gudny Eiriksdottir; Ann Rumley; Gordon D O Lowe; Mark B Pepys; Vilmundur Gudnason
Journal:  N Engl J Med       Date:  2004-04-01       Impact factor: 91.245

6.  The high molecular weight form of endothelial cell von Willebrand factor is released by the regulated pathway.

Authors:  H M Tsai; R L Nagel; V B Hatcher; A C Seaton; I I Sussman
Journal:  Br J Haematol       Date:  1991-10       Impact factor: 6.998

7.  Elevated glucose concentrations increase factor VIIIR:Ag levels in human umbilical vein endothelial cells.

Authors:  D B Mordes; J Lazarchick; J A Colwell; D A Sens
Journal:  Diabetes       Date:  1983-09       Impact factor: 9.461

8.  Endothelial cell markers and the risk of coronary heart disease: the Prospective Epidemiological Study of Myocardial Infarction (PRIME) study.

Authors:  P E Morange; C Simon; M C Alessi; G Luc; D Arveiler; J Ferrieres; P Amouyel; A Evans; P Ducimetiere; I Juhan-Vague
Journal:  Circulation       Date:  2004-03-15       Impact factor: 29.690

9.  Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion.

Authors:  H M Tsai
Journal:  Blood       Date:  1996-05-15       Impact factor: 22.113

10.  Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis.

Authors:  M Furlan; R Robles; B Lämmle
Journal:  Blood       Date:  1996-05-15       Impact factor: 22.113

View more
  36 in total

1.  Decreased expression of microRNAs targeting type-2 diabetes susceptibility genes in peripheral blood of patients and predisposed individuals.

Authors:  Ioanna Kokkinopoulou; Eirini Maratou; Panayota Mitrou; Eleni Boutati; Diamantis C Sideris; Emmanuel G Fragoulis; Maria-Ioanna Christodoulou
Journal:  Endocrine       Date:  2019-09-26       Impact factor: 3.633

2.  α-galactosidase A deficiency promotes von Willebrand factor secretion in models of Fabry disease.

Authors:  Justin J Kang; Nayiri M Kaissarian; Karl C Desch; Robert J Kelly; Liming Shu; Peter F Bodary; James A Shayman
Journal:  Kidney Int       Date:  2018-11-22       Impact factor: 10.612

3.  MicroRNA-24 inhibits the proliferation and migration of endothelial cells in patients with atherosclerosis by targeting importin-α3 and regulating inflammatory responses.

Authors:  Ye Zheng; Yongxing Li; Gang Liu; Xiangqian Qi; Xufen Cao
Journal:  Exp Ther Med       Date:  2017-10-23       Impact factor: 2.447

4.  miR-23b-3p induces the cellular metabolic memory of high glucose in diabetic retinopathy through a SIRT1-dependent signalling pathway.

Authors:  Shuzhi Zhao; Tao Li; Jun Li; Qianyi Lu; Changjing Han; Na Wang; Qinghua Qiu; Hui Cao; Xun Xu; Haibing Chen; Zhi Zheng
Journal:  Diabetologia       Date:  2015-12-19       Impact factor: 10.122

Review 5.  Versatile role of miR-24/24-1*/24-2* expression in cancer and other human diseases.

Authors:  Sanjukta Mukherjee; Bhagyashree Shelar; Sudhir Krishna
Journal:  Am J Transl Res       Date:  2022-01-15       Impact factor: 4.060

6.  Single-cell transcriptional analysis of human endothelial colony-forming cells from patients with low VWF levels.

Authors:  Christopher J Ng; Alice Liu; Sujatha Venkataraman; Katrina J Ashworth; Christopher D Baker; Rebecca O'Rourke; Rajeev Vibhakar; Kenneth L Jones; Jorge Di Paola
Journal:  Blood       Date:  2022-04-07       Impact factor: 22.113

Review 7.  Regulation of VWF expression, and secretion in health and disease.

Authors:  Yaozu Xiang; John Hwa
Journal:  Curr Opin Hematol       Date:  2016-05       Impact factor: 3.284

8.  Evaluation of Serum miRNA-24, miRNA-29a and miRNA-502-3p Expression in PCOS Subjects: Correlation with Biochemical Parameters Related to PCOS and Insulin Resistance.

Authors:  Dipti Nanda; Sathiya Priya Chandrasekaran; Vidhya Ramachandran; Kalpana Kalaivanan; Anuradha Carani Venkatraman
Journal:  Indian J Clin Biochem       Date:  2019-01-03

9.  P66Shc-Induced MicroRNA-34a Causes Diabetic Endothelial Dysfunction by Downregulating Sirtuin1.

Authors:  Qiuxia Li; Young-Rae Kim; Ajit Vikram; Santosh Kumar; Modar Kassan; Mohanad Gabani; Sang Ki Lee; Julia S Jacobs; Kaikobad Irani
Journal:  Arterioscler Thromb Vasc Biol       Date:  2016-10-27       Impact factor: 8.311

10.  GALLIC ACID IMPROVES OXIDATIVE STRESS AND INFLAMMATION THROUGH REGULATING MICRORNAS EXPRESSIONS IN THE BLOOD OF DIABETIC RATS.

Authors:  F Ramezani Ali Akbari; M Badavi; M Dianat; S A Mard; A Ahangarpour
Journal:  Acta Endocrinol (Buchar)       Date:  2019 Apr-Jun       Impact factor: 0.877

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.